JP2017513913A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017513913A5 JP2017513913A5 JP2016564604A JP2016564604A JP2017513913A5 JP 2017513913 A5 JP2017513913 A5 JP 2017513913A5 JP 2016564604 A JP2016564604 A JP 2016564604A JP 2016564604 A JP2016564604 A JP 2016564604A JP 2017513913 A5 JP2017513913 A5 JP 2017513913A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- disorder
- converting
- iii
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 44
- 238000000034 method Methods 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- GPWNWKWQOLEVEQ-UHFFFAOYSA-N 2,4-diaminopyrimidine-5-carbaldehyde Chemical compound NC1=NC=C(C=O)C(N)=N1 GPWNWKWQOLEVEQ-UHFFFAOYSA-N 0.000 claims description 8
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 claims description 8
- 125000002777 acetyl group Chemical class [H]C([H])([H])C(*)=O 0.000 claims description 8
- 230000004913 activation Effects 0.000 claims description 8
- 150000001408 amides Chemical class 0.000 claims description 8
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 claims description 8
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 8
- 239000003153 chemical reaction reagent Substances 0.000 claims description 8
- 230000008878 coupling Effects 0.000 claims description 8
- 238000010168 coupling process Methods 0.000 claims description 8
- 238000005859 coupling reaction Methods 0.000 claims description 8
- 229910052751 metal Inorganic materials 0.000 claims description 8
- 239000002184 metal Substances 0.000 claims description 8
- 208000012902 Nervous system disease Diseases 0.000 claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 238000007171 acid catalysis Methods 0.000 claims description 4
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims description 4
- 150000001412 amines Chemical class 0.000 claims description 4
- 125000000129 anionic group Chemical group 0.000 claims description 4
- 239000003054 catalyst Substances 0.000 claims description 4
- 238000004296 chiral HPLC Methods 0.000 claims description 4
- 229910052802 copper Inorganic materials 0.000 claims description 4
- 238000007333 cyanation reaction Methods 0.000 claims description 4
- 206010015037 epilepsy Diseases 0.000 claims description 4
- 230000003301 hydrolyzing effect Effects 0.000 claims description 4
- 150000002825 nitriles Chemical class 0.000 claims description 4
- 208000028173 post-traumatic stress disease Diseases 0.000 claims description 4
- 239000000376 reactant Substances 0.000 claims description 4
- 201000000980 schizophrenia Diseases 0.000 claims description 4
- 229910052725 zinc Inorganic materials 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 208000019901 Anxiety disease Diseases 0.000 claims description 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 2
- 206010003805 Autism Diseases 0.000 claims description 2
- 208000020706 Autistic disease Diseases 0.000 claims description 2
- 208000006373 Bell palsy Diseases 0.000 claims description 2
- 208000020925 Bipolar disease Diseases 0.000 claims description 2
- 206010012289 Dementia Diseases 0.000 claims description 2
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims description 2
- 102100039856 Histone H1.1 Human genes 0.000 claims description 2
- 101001035402 Homo sapiens Histone H1.1 Proteins 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 2
- 208000002193 Pain Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 206010034912 Phobia Diseases 0.000 claims description 2
- 208000028017 Psychotic disease Diseases 0.000 claims description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 2
- 208000011963 Substance-induced psychotic disease Diseases 0.000 claims description 2
- 231100000393 Substance-induced psychotic disorder Toxicity 0.000 claims description 2
- 208000000323 Tourette Syndrome Diseases 0.000 claims description 2
- 208000016620 Tourette disease Diseases 0.000 claims description 2
- 208000036826 VIIth nerve paralysis Diseases 0.000 claims description 2
- 201000007201 aphasia Diseases 0.000 claims description 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 2
- 206010008129 cerebral palsy Diseases 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 201000002545 drug psychosis Diseases 0.000 claims description 2
- 206010014599 encephalitis Diseases 0.000 claims description 2
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 206010022437 insomnia Diseases 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 208000019906 panic disease Diseases 0.000 claims description 2
- 208000019899 phobic disease Diseases 0.000 claims description 2
- 229940002612 prodrug Drugs 0.000 claims description 2
- 239000000651 prodrug Substances 0.000 claims description 2
- 230000005855 radiation Effects 0.000 claims description 2
- 208000019116 sleep disease Diseases 0.000 claims description 2
- 208000020685 sleep-wake disease Diseases 0.000 claims description 2
- 239000012453 solvate Substances 0.000 claims description 2
- 201000001119 neuropathy Diseases 0.000 claims 3
- 230000007823 neuropathy Effects 0.000 claims 3
- 208000033808 peripheral neuropathy Diseases 0.000 claims 3
- 208000027448 Attention Deficit and Disruptive Behavior disease Diseases 0.000 claims 1
- 208000027099 Paranoid disease Diseases 0.000 claims 1
- 208000035548 disruptive behavior disease Diseases 0.000 claims 1
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- 208000024254 Delusional disease Diseases 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000002851 paranoid schizophrenia Diseases 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461985381P | 2014-04-28 | 2014-04-28 | |
| US61/985,381 | 2014-04-28 | ||
| US201462047569P | 2014-09-08 | 2014-09-08 | |
| US62/047,569 | 2014-09-08 | ||
| PCT/US2015/027645 WO2015167968A1 (en) | 2014-04-28 | 2015-04-24 | Optically active pde10 inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017513913A JP2017513913A (ja) | 2017-06-01 |
| JP2017513913A5 true JP2017513913A5 (cg-RX-API-DMAC7.html) | 2018-05-31 |
Family
ID=54359189
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016564604A Pending JP2017513913A (ja) | 2014-04-28 | 2015-04-24 | 光学活性なｐｄｅ１０阻害剤 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9493447B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3137461B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2017513913A (cg-RX-API-DMAC7.html) |
| KR (1) | KR102558505B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN106255690B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2015253463B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112016024523B1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2946754C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2895487T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL248586B (cg-RX-API-DMAC7.html) |
| NZ (2) | NZ716462A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2016146097A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015167968A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2544679T3 (pl) * | 2010-03-12 | 2019-10-31 | Omeros Corp | Inhibitory PDE10 oraz powiązane kompozycje i sposoby |
| NZ716462A (en) * | 2014-04-28 | 2017-11-24 | Omeros Corp | Optically active pde10 inhibitor |
| NZ716494A (en) * | 2014-04-28 | 2017-07-28 | Omeros Corp | Processes and intermediates for the preparation of a pde10 inhibitor |
| US20160284909A1 (en) * | 2015-03-27 | 2016-09-29 | Gabriel Harley | Multi-diode solar cells |
| CA2980801A1 (en) * | 2015-04-24 | 2016-10-27 | Omeros Corporation | Pde10 inhibitors and related compositions and methods |
| US9920045B2 (en) | 2015-11-04 | 2018-03-20 | Omeros Corporation | Solid state forms of a PDE10 inhibitor |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK178590D0 (da) | 1990-07-26 | 1990-07-26 | Novo Nordisk As | 1,4-disubstituerede piperaziner |
| PT100905A (pt) | 1991-09-30 | 1994-02-28 | Eisai Co Ltd | Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem |
| RU95113454A (ru) | 1992-12-02 | 1997-06-10 | Пфайзер Инк. (US) | Катехольные диэфиры как селективные ингибиторы фдэiv, фармацевтическая композиция, способы лечения |
| DE4323192A1 (de) | 1993-07-10 | 1995-01-12 | Basf Ag | Verfahren zur Herstellung von Homo- und Copolymerisaten von Alk-1-enen |
| DE4325846C1 (de) | 1993-07-31 | 1995-01-19 | Herberts Gmbh | Verwendung von Furan-modifizierten aromatischen Pinakolderivaten als Initiatoren und Furan-modifizierte aromatische Pinakolderivate als solche |
| DE4343286A1 (de) | 1993-12-17 | 1995-06-22 | Hoechst Ag | Heteroaromatische Verbindungen und ihre Verwendung in flüssigkristallinen Mischungen |
| DE4409501A1 (de) | 1994-03-19 | 1995-09-21 | Didier Werke Ag | Verschleißfutter eines Schachtofens und Stein hierfür |
| AU695230B2 (en) | 1994-06-24 | 1998-08-06 | Euro-Celtique S.A. | Compounds for and method of inhibiting phosphodiesterase IV |
| US5789434A (en) | 1994-11-15 | 1998-08-04 | Bayer Corporation | Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors |
| TW332201B (en) | 1995-04-06 | 1998-05-21 | Janssen Pharmaceutica Nv | 1,3-Dihydro-1-(phenylalkyl)-2H-imidazol-2-one derivatives |
| TW424087B (en) | 1995-04-06 | 2001-03-01 | Janssen Pharmaceutica Nv | 1,3-dihydro-1-(phenylalkenyl)-2H-imidazol-2-one derivatives |
| US6037370A (en) | 1995-06-08 | 2000-03-14 | Vertex Pharmaceuticals Incorporated | Methods and compositions for stimulating neurite growth |
| EA199800650A1 (ru) | 1996-01-22 | 1999-02-25 | Фудзисава, Фармасьютикал Ко., Лтд | Новые соединения |
| AU4015497A (en) | 1996-08-26 | 1998-03-19 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Thiazole derivatives useful as selective inhibitors of pde-iv |
| JPH1087543A (ja) | 1996-09-17 | 1998-04-07 | Chisso Corp | アルコキシベンゼン誘導体、液晶組成物および液晶表示素子 |
| US6548490B1 (en) | 1997-10-28 | 2003-04-15 | Vivus, Inc. | Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction |
| WO1999045914A1 (en) | 1998-03-13 | 1999-09-16 | Maruho Kabushikikaisha | Alkyl amine derivative and local anesthetic agent using the same |
| GB9807354D0 (en) * | 1998-04-07 | 1998-06-03 | Glaxo Group Ltd | Antiviral compound |
| SE9804212D0 (sv) | 1998-12-04 | 1998-12-04 | Astra Pharma Prod | Compounds |
| WO2000034251A1 (en) | 1998-12-07 | 2000-06-15 | Smithkline Beecham Corporation | A method for quantitative determination of amino acids |
| SI1165516T1 (sl) | 1999-03-12 | 2005-02-28 | Boehringer Ingelheim Pharmaceuticals Inc. | Heterociklična sečnina in sorodne spojine, uporabne kot protivnetna sredstva |
| US7141593B1 (en) * | 1999-06-04 | 2006-11-28 | Abbott Laboratories | Pharmaceutical formulations |
| GB9929552D0 (en) | 1999-12-14 | 2000-02-09 | Proteus Molecular Design | Compounds |
| WO2001096334A2 (en) | 2000-06-15 | 2001-12-20 | Pharmacia Corporation | Heteroarylalkanoic acids as integrin receptor antagonists |
| US20030032579A1 (en) | 2001-04-20 | 2003-02-13 | Pfizer Inc. | Therapeutic use of selective PDE10 inhibitors |
| JP2004530703A (ja) * | 2001-05-22 | 2004-10-07 | ファイザー・プロダクツ・インク | 結晶形アジスロマイシン |
| US6821502B2 (en) * | 2002-06-12 | 2004-11-23 | Chevron U.S.A. Inc. | Method of making aluminum-containing zeolite with IFR structure |
| WO2004011410A1 (en) | 2002-07-27 | 2004-02-05 | Astrazeneca Ab | Chemical compounds |
| MXPA05003762A (es) | 2002-10-08 | 2005-07-22 | Scripps Research Inst | Inhibidores de hidrolasa de amida de acido graso. |
| WO2004041258A2 (fr) | 2002-10-30 | 2004-05-21 | Neuro3D | Utilisation d’inhibiteurs des phosphodiesterases des nucleotides cycliques, ayant une structure benzodiazepinique en therapie |
| TW200410921A (en) | 2002-11-25 | 2004-07-01 | Hoffmann La Roche | Mandelic acid derivatives |
| EP1568691A4 (en) | 2002-12-06 | 2010-08-25 | Kowa Co | ACCELERATOR FOR ERYTHROPOETIN PRODUCTION |
| MXPA05006727A (es) | 2002-12-20 | 2005-09-08 | Pharmacia Corp | Acidos heteroarilalcanoicos como antagonistas de receptor de integrina. |
| WO2004071509A1 (ja) | 2003-02-12 | 2004-08-26 | Nippon Chemiphar Co., Ltd. | オリゴデンドロサイト分化促進剤 |
| AU2004232973A1 (en) | 2003-04-18 | 2004-11-04 | Memory Pharmaceuticals Corporation | Pyrazole derivatives as phosphodiesterase 4 inhibitors |
| AR047541A1 (es) * | 2004-02-13 | 2006-01-25 | Sandoz Ag | Fosfato de 5-[[4-[2-metil-2-piridinil-amino-etoxi]fenil]metil]-2,4 tiazolidinadiona (rosiglitazona) y sus formas polimorficas |
| NZ550114A (en) | 2004-04-20 | 2011-02-25 | Transtech Pharma Inc | Substituted thiazole and pyrimidine derivatives as melanocortin receptor modulators |
| US20060074102A1 (en) | 2004-05-14 | 2006-04-06 | Kevin Cusack | Kinase inhibitors as therapeutic agents |
| US7351833B2 (en) * | 2004-07-23 | 2008-04-01 | Abbott Laboratories | (1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate |
| US7449486B2 (en) | 2004-10-19 | 2008-11-11 | Array Biopharma Inc. | Mitotic kinesin inhibitors and methods of use thereof |
| US8436176B2 (en) * | 2004-12-30 | 2013-05-07 | Medicis Pharmaceutical Corporation | Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine |
| UA86283C2 (uk) | 2005-01-07 | 2009-04-10 | Пфайзер Продактс Инк. | Гетероароматичні сполуки хіноліну і їх застосування як інгібіторів pde10 |
| EP1850681B1 (en) | 2005-02-04 | 2019-12-18 | Firmenich Incorporated | Compounds comprising linked hetero aryl moieties and their use as novel umami flavor modifiers, tastants and taste enhancers for comestible compositions |
| US20060252807A1 (en) | 2005-04-22 | 2006-11-09 | Kalypsys, Inc. | Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders |
| UA91546C2 (uk) * | 2005-05-03 | 2010-08-10 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ |
| MY152185A (en) * | 2005-06-10 | 2014-08-29 | Novartis Ag | Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation |
| EP1928848A2 (en) | 2005-08-04 | 2008-06-11 | Apogee Biothechnology Corporation | Sphingosine kinase inhibitors and methods of their use |
| KR20080050577A (ko) * | 2005-08-29 | 2008-06-09 | 사노피-아벤티스 유.에스. 엘엘씨 | 피리다지노[4,5-ｂ]인돌 유도체의 신규 결정질 형태 |
| US7642246B2 (en) * | 2005-09-13 | 2010-01-05 | Sicor Inc. | Pure rocuronium bromide |
| SI1954684T1 (sl) | 2005-11-15 | 2014-07-31 | Otsuka Pharmaceutical Co., Ltd. | Oksazolna spojina in farmacevtski sestavek |
| EP1968946A4 (en) | 2005-12-23 | 2010-05-05 | Astrazeneca Ab | IMIDAZOLE AS MODULATORS OF THE GABA B RECEPTOR |
| JP2009535394A (ja) | 2006-05-02 | 2009-10-01 | ファイザー・プロダクツ・インク | Ｐｄｅ１０阻害剤としての二環式ヘテロアリール化合物 |
| US20080090834A1 (en) | 2006-07-06 | 2008-04-17 | Pfizer Inc | Selective azole pde10a inhibitor compounds |
| US20080234345A1 (en) | 2006-09-08 | 2008-09-25 | Gene Logic Inc. | Method for reducing or alleviating inflammation in the digestive tract |
| SG185979A1 (en) | 2006-09-25 | 2012-12-28 | Ptc Therapeutics Inc | Crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid |
| EP2079462A4 (en) * | 2006-09-28 | 2009-12-02 | Merck & Co Inc | PHARMACEUTICAL COMPOSITIONS OF HDAC INHIBITORS AND CHELABLE METAL COMPOUNDS AND METALO HDAC HEMMER CHELATE COMPLEXES |
| WO2008040669A2 (en) | 2006-10-02 | 2008-04-10 | Janssen Pharmaceutica N.V. | Novel intermediates for the preparation of a glyt1 inhibitor |
| US7837978B2 (en) * | 2006-10-13 | 2010-11-23 | Chevron U.S.A. Inc. | Process for preparing aluminum-containing molecular sieve SSZ-26 |
| US7786139B2 (en) | 2006-11-21 | 2010-08-31 | Omeros Corporation | PDE10 inhibitors and related compositions and methods |
| ES2624791T3 (es) | 2006-11-21 | 2017-07-17 | Omeros Corporation | Inhibidores de PDE10 y composiciones y métodos relacionados |
| PE20081506A1 (es) * | 2006-12-12 | 2008-12-09 | Infinity Discovery Inc | Formulaciones de ansamicina |
| WO2009008906A2 (en) | 2007-02-06 | 2009-01-15 | The Trustees Of The University Of Pennsylvania | Therapeutic compounds for blocking dna synthesis of pox viruses |
| AU2008253803A1 (en) * | 2007-05-22 | 2008-11-27 | Ultimorphix Technolgies B.V. | Tenofovir disoproxil hemi-fumaric acid Co-crystal |
| EP2017264A1 (de) | 2007-07-16 | 2009-01-21 | Bayer Cropscience Ag | Substituierte Phenylpropargylverbindungen, Verfahren zu deren Herstellung und deren Verwendung als Herbizide und Pflanzenwachstumsregulatoren |
| WO2009049022A1 (en) | 2007-10-10 | 2009-04-16 | Ore Pharmaceuticals Inc. | Method for treatment of pancreatitis |
| TW200944520A (en) * | 2008-01-29 | 2009-11-01 | Glaxo Group Ltd | Spiro compounds as NPY Y5 receptor antagonists |
| WO2009143178A2 (en) | 2008-05-20 | 2009-11-26 | Omeros Corporation | Pde10 inhibitors and related compositions and methods |
| TWI501965B (zh) | 2008-06-20 | 2015-10-01 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物 |
| US8377930B2 (en) | 2008-08-05 | 2013-02-19 | Omeros Corporation | PDE10 inhibitors and related compositions and methods |
| PL2544679T3 (pl) * | 2010-03-12 | 2019-10-31 | Omeros Corp | Inhibitory PDE10 oraz powiązane kompozycje i sposoby |
| NZ716462A (en) * | 2014-04-28 | 2017-11-24 | Omeros Corp | Optically active pde10 inhibitor |
| NZ716494A (en) * | 2014-04-28 | 2017-07-28 | Omeros Corp | Processes and intermediates for the preparation of a pde10 inhibitor |
-
2014
- 2014-09-10 NZ NZ716462A patent/NZ716462A/en unknown
- 2014-09-10 NZ NZ630803A patent/NZ630803A/en unknown
-
2015
- 2015-04-24 CN CN201580023106.6A patent/CN106255690B/zh active Active
- 2015-04-24 BR BR112016024523-7A patent/BR112016024523B1/pt active IP Right Grant
- 2015-04-24 JP JP2016564604A patent/JP2017513913A/ja active Pending
- 2015-04-24 WO PCT/US2015/027645 patent/WO2015167968A1/en not_active Ceased
- 2015-04-24 ES ES15785340T patent/ES2895487T3/es active Active
- 2015-04-24 EP EP15785340.9A patent/EP3137461B1/en active Active
- 2015-04-24 US US14/696,295 patent/US9493447B2/en active Active
- 2015-04-24 CA CA2946754A patent/CA2946754C/en active Active
- 2015-04-24 KR KR1020167031125A patent/KR102558505B1/ko active Active
- 2015-04-24 AU AU2015253463A patent/AU2015253463B2/en active Active
- 2015-04-24 RU RU2016146097A patent/RU2016146097A/ru not_active Application Discontinuation
-
2016
- 2016-10-12 US US15/291,948 patent/US9850238B2/en active Active
- 2016-10-27 IL IL248586A patent/IL248586B/en active IP Right Grant